Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

NCT05338697 · View on ClinicalTrials.gov ↗

Study Summary

VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.

Interventions

  • DIAGNOSTIC_TEST Transcranial Magnetic Stimulation (TMS)

Study Locations (20)

California

  • Keck Medical Center of USC — Los Angeles
  • Ronald Reagan UCLA Medical Center — Los Angeles
  • Kaiser Permanente Redwood City Medical Center — Redwood City
  • San Francisco General Hospital — San Francisco
  • UCSF Medical Center — San Francisco

Massachusetts

  • Massachusetts General Hospital — Boston
  • Lahey Hospital & Medical Center — Burlington
  • Baystate Medical Center — Springfield

Alabama

  • Birmingham VA Medical Center — Birmingham
  • University of Alabama — Birmingham

Illinois

  • Memorial Hospital of Carbondale — Carbondale
  • Advocate Lutheran General Hospital — Park Ridge

Arizona

  • Banner University Medical Center — Tucson

Connecticut

  • Yale New Haven Hospital — New Haven

District of Columbia

  • MedStar Washington Hospital Center — Washington D.C.

Georgia

  • Emory University Hospital — Atlanta

Trial Details

FieldValue
Enrollment Target 657 participants
Start Date 2022-06-18
Est. Completion 2027-10

Sponsor

University of Cincinnati

179 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05338697

The ClinicalTrials.gov registry entry for NCT05338697 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 657 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 179 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention — of which Transcranial Magnetic Stimulation (TMS) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05338697 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Massachusetts, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05338697 about?

NCT05338697 is a clinical study titled "Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials". VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, tran...

What is the current status of trial NCT05338697?

This trial is currently recruiting. The enrollment target is 657 participants. The study started on 2022-06-18. Estimated completion is 2027-10.

What conditions does trial NCT05338697 study?

This clinical trial studies the following conditions: Stroke, Stroke, Ischemic, Stroke, Acute. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05338697?

The interventions under investigation include: Transcranial Magnetic Stimulation (TMS) (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05338697?

This trial is sponsored by University of Cincinnati, which has 179 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05338697 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial